24 Hour Toll Free Help

Do I Have a Personal Injury Claim for Taking Farxiga

Do I have a personal injury claim for taking Farxiga? If you are asking this question, it is probably because you have suffered diabetic ketoacidosis and/or other serious side effects as a result of taking this medication.

Farxiga is the brand name under which the drug dapagliflozin is sold. Dapagliflozin is a member of the gliflozin class of drugs. Gliflozin drugs are a class of drugs that inhibit renal glucose reabsorption. As a result, they lower blood glucose (sugar). They are used in the treatment of type 2 diabetes.

These drugs act by inhibiting sodium-glucose transport protein 2 (SGLT2). Because of this, gliflozin drugs are also known as SGLT2 inhibitors.


Farxiga (dapagliflozin) was developed by Bristol-Myers Squibb in partnership with AstraZeneca. In July 2011, a U.S. Food and Drug Administration (FDA) committee recommended against approval of the drug dapagliflozin until more data was available.

On January 8, 2014, the FDA approved dapagliflozin for glycemic control, along with diet and exercise, in adults who had type 2 diabetes. When AstraZeneca gained this approval from the FDA, it was only the second FDA-approved drug in a new class of diabetes drugs that are called sodium-glucose cotransporter-2 (SGLT2) inhibitors.

As mentioned above, Farxiga is used in the treatment of type 2 diabetes. Farxiga works by helping your kidneys get rid of glucose (sugar) in your bloodstream.


However, in March 2015, according to a Safety Communication from the FDA, Farxiga and other drugs in the SGLT2 inhibitor class had been linked to a risk of diabetic ketoacidosis.

Diabetic ketoacidosis is a serious complication of diabetes that occurs when your body produces high levels of blood acids that are known as ketones. The ketones are produced when your body does not have enough insulin. This forces your body to burn fat cells for fuel.

An FDA review of adverse events found that 20 cases of diabetic ketoacidosis were associated with SGLT2 inhibitors between March 2013 and June 2014. Even more cases have been identified since this time. Victims required emergency medical treatment or had to be hospitalized.

Bladder cancer

During clinical trials, Farxiga was also associated with 10 instances of bladder cancer. The FDA has asked AstraZeneca to monitor bladder cancer rates and warn physicians against giving the medication to high-risk patients, as well as including warnings concerning this possible side effect on the label of the medication.

In addition, a consumer advocacy group, Public Citizen, sent a letter to the FDA demanding that civil fines and warning letters be issued against AstraZeneca. The reason for this was concern that AstraZeneca was conducting illegal “off-label” (unapproved) marketing of Farxiga as a weight-loss product. Fine print on the label of Farxiga indicate that clinical trials had suggested the benefit of possible weight loss, even though the drug has never been evaluated as an effective and safe weight-loss product.

Once again, if you are thinking about pursuing a personal injury claim because you suffered diabetic ketoacidosis and/or other serious side effects after taking Farxiga, you should call a personal injury attorney and have your case evaluated at no cost or obligation to you.

Article written by James Shugart

Connect with James on Google+